Siemens Healthineers AG/ADR
SMMNYDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
Get an email about SMMNY's next catalysts
Track Siemens Healthineers AG/ADR (SMMNY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
68Ga- PSMA-HBED-CC
Prostate Cancer
Cisplatin injection
Head and Neck Squamous Cell Carcinoma
Sonazoid; Perflubutane for Injection
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
68Ga- PSMA-HBED-CC | Phase 3 | Prostate Cancer | - | - |
Cisplatin injection | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Sonazoid; Perflubutane for Injection | Phase 2 | Breast Cancer | - | - |
Frequently asked questions
What is in Siemens Healthineers AG/ADR's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Siemens Healthineers AG/ADR's (SMMNY) pipeline across Phase 3, Phase 2. Its lead program is 68Ga- PSMA-HBED-CC (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Siemens Healthineers AG/ADR's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Siemens Healthineers AG/ADR (SMMNY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SMMNY biotech catalysts?→
Add SMMNY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Siemens Healthineers AG/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.